Regulatory Operations: The Overlooked Half of Submission Readiness 

A marketing application is judged on the strength of its scientific evidence. But regulators can only evaluate that evidence when it has been translated into a complete, technically compliant, internally consistent, and navigable application. 

That is why a complete dossier is not necessarily a submission-ready dossier. 

Regulatory operations is too often positioned at the end of the submission journey: completed documents are handed to a publishing team, assembled into an electronic common technical document (eCTD), and filed. In reality, delivering a high-quality eCTD requires sustained operational planning and execution that progresses in parallel with regulatory strategy and content development. 

This blog explores the operational foundations of submission readiness, from publishing expertise and infrastructure to quality control, evolving eCTD standards, and integrated project planning. 

The Expertise Behind a High-Quality Submission 

Publishing a New Drug Application (NDA) or Marketing Authorization Application (MAA) is not simply a matter of operating publishing software. It is a specialized technical discipline requiring a deep understanding of eCTD architecture, validation criteria, technical specifications, metadata, document lifecycle, and the navigational infrastructure reviewers rely on to move efficiently through an extensive application. 

Experienced publishers also bring foresight. They recognize common submission vulnerabilities, understand how issues can affect downstream activities, and can often prevent problems before they emerge. 

The readiness question, therefore, is not simply whether publishing resources are available. It is whether the team has enough experienced publishers and sufficient capacity to respond as document volume accelerates. Without that depth and flexibility, even a scientifically complete dossier can encounter operational constraints as filing approaches. 

Bring Regulatory Operations into the Readiness Assessment 

Operational readiness should be evaluated alongside content readiness. An early operational gap analysis gives the publishing team visibility into the anticipated application and an opportunity to shape the submission approach before dossier assembly begins. 

This assessment may include developing a preliminary table of contents, reviewing the quality and format of available documents, determining whether existing investigational new drug application content can be repurposed, and identifying content that will require additional preparation. 

It should also evaluate the infrastructure that will support the submission. Project-tracking systems need to provide visibility across modules, source documents, owners, review cycles, and due dates. Document management controls must preserve version integrity, while templates, styles, and publishing workflows should be standardized before large volumes of content begin moving through the process. The goal is to identify operational constraints while there is still time to address them systematically. 

Build Quality into Every Stage 

A clean, technically compliant eCTD is not produced through a final assembly exercise. It is built through a controlled sequence of document preparation, publishing, quality control, technical validation, and dossier assembly. 

Rather than waiting until every document is complete, finalized content should move to regulatory operations on a rolling basis. Publishers can standardize formatting, create submission-ready PDFs, incorporate content into the eCTD structure, and perform technical quality control as the application develops. In parallel, content owners can verify scientific accuracy and completeness. 

Technical validation should also run continuously. Broken links, metadata errors, formatting inconsistencies, and other deficiencies are easier to address while individual sections are being built than after the full application has been assembled. Once a section has completed content and publishing review and passed validation, it can effectively be locked. By filing day, much of the application has already progressed through multiple layers of review. 

Plan for Evolving Submission Standards 

Operational planning must also account for the transition to eCTD 4.0, which introduces changes to technical architecture, document hierarchy, metadata, and document lifecycle capabilities. These changes have implications for technology, processes, training, and submission planning—not simply the final publishing format. 

In Europe, eCTD 4.0 has been available for optional use for new centrally authorized product (CAP) MAAs since December 2025. EMA plans to strongly recommend its use beginning in Q1 2027 and require it for new CAP MAAs beginning in Q1 2028, while eCTD 3.2.2 continues to be accepted during the transition. ⁱ 

In the U.S., FDA has accepted new regulatory applications in eCTD 4.0 since September 2024, while continuing to support eCTD 3.2.2. The agency is progressing toward broader implementation, including plans to enable existing eCTD 3.2.2 applications to transition to v4.0, as adoption expands over the coming years. ⁱⁱ 

For programs approaching an NDA and MAA in parallel, these differing timelines create an important planning consideration. Teams need to assess which eCTD version is appropriate for each application, whether the necessary tools and expertise are available, and how those decisions may influence content planning and harmonization across regions. This makes eCTD version strategy a joint consideration for regulatory strategy and regulatory operations rather than a publishing decision made in isolation. 

Turn the Timeline into an Integrated Operating Plan 

Submission readiness ultimately depends on coordination across regulatory strategy, CMC, nonclinical, clinical, biostatistics, medical writing, and publishing. A detailed project plan should connect these workstreams through shared milestones, dependencies, ownership, review cycles, and finalization dates. 

Visibility at the source-document level is equally important. Teams need to know who owns each deliverable, when drafts and reviews are due, and where delays may affect downstream activities. Dashboards can help surface upcoming milestones and at-risk items early enough for the team to respond before they threaten the broader submission timeline. 

Operational readiness also continues after transmission. The submission team should remain positioned to support the agency’s initial filing review and respond efficiently to questions and information requests as review progresses. 

The objective is not simply to submit on time. It is to deliver a technically sound application supported by the people, processes, and infrastructure needed to move efficiently from preparation through agency review. 

When regulatory operations is embedded in readiness planning from the outset, the eCTD becomes the product of a disciplined, integrated process—giving reviewers a well-structured application in which the science can remain the focus. 

Successful submission readiness depends on more than complete content. Premier Research brings together regulatory strategy, regulatory operations, publishing expertise, technology, and integrated project planning to identify gaps early, establish the right operational infrastructure, and support a high-quality NDA or MAA from readiness assessment through filing and agency review. Contact us today to discuss your submission plan. 

ABOUT PREMIER RESEARCH:  

Premier Research International LLC (Premier) is a global leader in clinical research and consulting services with expertise in driving an efficient and effective path to market for the life sciences industry.  

Premier is built with the needs of biotech in mind, turning breakthrough science into life-changing drugs, devices, and diagnostics by addressing trial complexity, overcoming development hurdles, and demonstrating product value.  

Leveraging deep therapeutic expertise, innovative technology, and product development operational proficiency—from preclinical planning to clinical trial execution and commercialization—our integrated approach offers personalized, end-to-end solutions to identify the pertinent data and insight necessary to make informed decisions earlier and deliver accelerated development timelines for a smarter, faster path to approval. To learn more visit premier-research.com.